<DOC>
	<DOCNO>NCT01039376</DOCNO>
	<brief_summary>The purpose study determine maintenance therapy ofatumumab prolong remission patient CLL respond second third line treatment . This study also evaluate safety ofatumumab maintenance compare observation ( current standard care ) . This study co-developed HOVON NORDIC CLL group conduct collaborative effort GSK .</brief_summary>
	<brief_title>Ofatumumab Maintenance Treatment vs No Further Treatment Relapsed CLL Responding Induction Therapy</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Adults document diagnosis CLL base modify IWCLL update NCIWG guideline ( Hallek , 2008 ) At least PR accord revised 2008 NCIWG CLL criterion , within 3 month response assessment last dose 2nd/3rd line treatment The antileukemic treatment study entry least 3 month 3 cycle ECOG Performance Status 02 Signed write informed consent prior perform studyspecific procedure Known primary secondary fludarabinerefractory subject , define treatment failure ( failure achieve CR PR ) disease progression within 6 month Prior maintenance therapy Known transformation CLL ( eg.Richter 's transformation ) , prolymphocytic leukemia ( PLL ) , CNS involvement CLL Active Autoimmune hemolytic anemia ( AIHA ) require treatment except opinion investigator medical monitor think affect subject 's safety , conduct study interpretation data Previous autologous allogeneic stem cell transplantation Chronic current active infectious disease require systemic antibiotic , antifungal , antiviral treatment , limited chronic renal infection , chronic chest infection bronchiectasis , tuberculosis active Hepatitis B C Other past current malignancy ( exception basal cell carcinoma skin situ carcinoma cervix breast ) unless tumor successfully treat curative intent least 2 year prior trial entry except opinion investigator medical monitor think affect subject 's safety , conduct study interpretation data Clinically significant cardiac disease , include unstable angina , acute myocardial infarction within 6 month prior screen , congestive heart failure , arrhythmia require therapy , exception exta systole minor conduction abnormality except opinion investigator medical monitor think affect subject 's safety , conduct study interpretation data History significant cerebrovascular disease event symptom sequelae Significant concurrent , uncontrolled medical condition opinion investigator GSK medical monitor contraindicates participation study Other antileukemic use medication include glucocorticoid Known HIV positive Screening laboratory value : platelet &lt; 50 x 109/L , neutrophil &lt; 1.0 x 109/L , Creatinine &gt; 1.5 X upper normal limit ( unless normal creatinine clearance ) , total bilirubin &gt; 1.5 X upper normal limit , ALT &gt; 2.5 X upper normal limit ( unless due liver involvement CLL ) , alkaline phosphase &gt; 2.5 X upper normal limit Known suspect hypersensitivity ofatumumab opinion investigator medical monitor contraindicates study participation Subjects receive treatment nonmarketed drug substance experimental therapy within 5terminal halflives 4 week whichever longer prior first dose study medication currently participate interventional clinical study Note : Participation interventional clinical study disease progression post PD followup permit Lactating woman , woman positive pregnancy test Visit 1 woman ( childbearing potential ) well men partner childbearing potential , willing use adequate contraception study start one year follow last ofatumumab dose . Adequate contraception define abstinence , oral hormonal birth control , implant levonorgestrel , estrogenic vaginal ring , percutaneous contraceptive patch , intrauterine device , male partner sterilization male partner sole partner subject . For female USA , use double barrier method also consider adequate ( condom occlusive cap plus spermicidal agent ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>maintenance therapy</keyword>
	<keyword>anti-CD20 monoclonal antibody</keyword>
	<keyword>ofatumumab</keyword>
</DOC>